Sanofi Ventures – focused on early-to-mid stage investing, company co-creation, leading financing rounds, and prioritising those companies advancing innovation – has announced an additional multi-year ...

Pharma companies in the UK are being invited to register their new medicines with both the MHRA and NICE at the same time, as part of a push to reduce regulatory review times by three to six months.

Roche's anti-CD20 antibody Gazyva has been on the market for more than a decade as a treatment for blood cancer, but could see a new lease of life if it gets FDA approval to treat kidney disease ...

AbbVie has filed for approval of a regimen based on its Venclexta therapy for previously untreated patients with chronic lymphocytic leukaemia (CLL), in combination with an AstraZeneca drug. The ...

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA ...

The 4th In Vivo Cell Engineering & Gene Editing Summit, taking place June 3–5, 2025 in Boston, is the definitive event dedicated to advancing next-generation in vivo cell and gene therapies from early ...

A report has suggested the UK is seeing an exodus of skilled science, technology, engineering, and mathematics (STEM) workers to other countries, placing the country's economic future at risk. The ...

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the company’s long ...

Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines. An unusual study presented at the European Society of Cardiology (ESC) congress in ...

Regeneron's PD-1 inhibitor Libtayo could find wider use for a form of skin cancer known as cutaneous squamous cell carcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million investment ...

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange. That valued the newly independent company at CHF 10.3 ...